American Strategic Investment (NYC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 29, 2025, with stockholders able to vote and submit questions online.
Stockholders will vote on the election of a Class II director, ratification of the independent auditor, a non-binding say-on-pay resolution, and other business.
Proxy materials are provided via internet access, with options for electronic or mail voting.
Voting matters and shareholder proposals
Proposals include electing Elizabeth K. Tuppeny as Class II director, ratifying PwC as auditor for 2025, and a non-binding advisory vote on executive compensation.
The Board recommends voting FOR all proposals.
Stockholders can submit proposals for the 2026 meeting by following procedures in the bylaws and SEC rules.
Board of directors and corporate governance
The Board consists of four members: three independent directors and one managing director.
Elizabeth K. Tuppeny is nominated for re-election; she and other directors have extensive industry and governance experience.
The Board has audit, compensation, and nominating/governance committees, all with independent members.
The lead independent director role enhances board independence and oversight.
The Board held eight meetings in 2024, with full attendance.
Latest events from American Strategic Investment
- Net loss narrowed and liquidity challenges persist amid NYC office market headwinds.NYC
Q2 2026 - Revenue fell to $7.3M as losses narrowed and portfolio remained 76.4% leased.NYC
Q1 2026 - Director elections, auditor change, and say-on-pay headline a governance-focused annual meeting.NYC
Proxy filing - Virtual 2026 meeting to vote on directors, auditor, and executive pay, with online participation.NYC
Proxy filing - 2025 saw lower revenue from asset sales but improved net loss and stable 80.3% occupancy.NYC
Q4 2025 - Virtual annual meeting to vote on director, auditor, and executive pay on May 29, 2025.NYC
Proxy Filing - Q3 net loss rose on impairments; 9 Times Square sale to cut leverage and boost diversification.NYC
Q3 2024 - $91.9M net loss on $84.7M impairment, $63.5M sale pending, EBITDA and occupancy up.NYC
Q2 2024 - Net loss narrowed in Q4 2024 as asset sales improved leverage and a new CEO was appointed.NYC
Q4 2024